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Background/aims: Little is known about the long-term outcome of chronic hepatitis B (CHB) patients who
discontinued antiviral therapy. We intended to analyze the long-term outcome of CHB patients who discontinued
lamivudine therapy and to evaluate predictors for post-treatment outcome.
Material/methods: From 2007 to 2008, 138 lamivudine off-treated CHB patients with alanine aminotransferase
normalization were consecutively enrolled. Post-treatment virologic relapse, biochemical breakthrough, hepatitis
flare, and retreatment results were retrospectively analyzed.
Results: Among 138 patients, 102 were initially HBeAg-positive at the start of lamivudine treatment. Virologic
relapse, biochemical breakthrough, and hepatitis flare were observed in 45.2, 52.9, and 12.7% of HBeAg-positive and
29.4, 30.6, and 8.3% of HBeAg-negative patients during the median follow-up of 28 and 30 months, respectively.
The cumulative virologic relapse and biochemical breakthrough rates were significantly lower in patients with HBV
DNA <50 copies/mL than 50-104 copies/mL at lamivudine cessation. Hepatitis flare was observed in 4.8 and 11.8%
of HBeAg-positive and HBeAg-negative patients with HBV DNA <50copies/mL, respectively. Thirty-eight among 138
patients received retreatment and most of them achieved biochemical (37/38) and virologic response (35/38)
within 1 year of retreatment. Undetectable serum HBV DNA (<50 copies/mL) and young age at lamivudine
cessation were inversely associated with virologic relapse. Undetectable HBV DNA at cessation, female, and initial
HBeAg-negative were inversely associated with biochemical breakthrough.
Conclusions: Post-treatment virologic relapse and biochemical breakthrough incidence were low in patients who
achieved undetectable viral titer at lamivudine cessation. Retreatment after biochemical breakthrough or virologic
relapse was safe and effective. Intermittent antiviral therapy might be cautiously considered in appropriately
selected CHB patients.
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Chronic hepatitis B (CHB) infection is estimated to
affect about 350 million persons worldwide [1]. Given
that a significant proportion of CHB patients develop
the complications of cirrhosis, end-stage liver disease or
even hepatocellular carcinoma over time [2,3], lamivu-
dine, which was the firstly approved oral nucleotide* Correspondence: kimkm70@amc.seoul.kr
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reproduction in any medium, provided the oranalogue (NA) for CHB treatment, has been shown to
reduce the risk of liver-related complications with suffi-
cient suppression of viral loads in CHB patients [2,4,5].
However, continued lamivudine therapy cannot always
maintain good antiviral responses over time due to inev-
itable appearance of drug resistance mutation [3,6-8].
Moreover, economic burden of long term lamivudine
therapy on an individual patient with HBV is big con-
straint [9,10], and further pregnancy may zeopardize the
long term lamivudine therapy and its outcome [11].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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therapy have been issued [12,13]. Currently, several CHB
treatment guidelines recommend that lamivudine could
be discontinued after consolidation therapy of at least 6-
12 months following achievement of undetectable serum
HBV DNA level and/or HBeAg loss/seroconversion
[3,8,14,15]. However, stopping lamivudine therapy is not
always easy since virologic relapse or biochemical break-
through including hepatitis flare are important concerns
both for CHB patients and clinicians [16]. In fact, post-
treatment virologic relapse is not rare, but the definite
endpoint of lamivudine therapy still remains to be eluci-
dated [12,13,17]. Moreover, little is known about the
long-term clinical course of CHB patients who discon-
tinued lamivudine therapy in terms of hepatitis flare and
retreatment result, and factors affecting long-term out-
comes of patients who discontinued lamivudine therapy
are still unclear.
In this retrospective study, we analyzed long-term
comprehensive clinical course of consecutive CHB
patients who were off-treated after sufficient lamivudine
treatment and tried to find out predisposing factors
which could influence the clinical outcome of these
patients. In addition, we intended to analyze the out-
come in re-treated patients after cessation of lamivudine.Figure 1 Flow sheet of enrolloment of the consecutive patients who
alanine aminotransferase.Patients and methods
Study subjects
Between January 2007 and December 2008, a total of
174 CHB patients discontinued lamivudine after at least
12 months treatment at our institution and they showed
normal alanine aminotransferase (ALT) level at the ces-
sation of lamivudine. None had previously been received
other nucleot(s)ide analogues or interferon-alpha before
lamivudine treatment. We tried to avoid selection bias
by enrolling all the consecutive patients who discontin-
ued lamivudine therapy regardless of the achievement of
virologic response in a given period (Figure 1). Thirty-
six out of a total of 174 patients were excluded since
they had a history of malignancy [breast (n = 2) and
lymphoma (n = 3)], they were younger than 16 years
(n = 8), or they administrated lamivudine for less than
12 months due to poor compliance (n = 23). The
remaining 138 consecutive patients were finally enrolled
in this retrospective analysis. ALT normalization was
defined by observation of ALT level less than 40 IU/L at
the time of lamivudine cessation because this study co-
hort was retrospectively collected.
This study protocol was approved by the Institutional
Review Board at Asan Medical Center, Seoul, Korea
(protocol number: 2010-0425).were off-treated after lamivudine treatment. LAM, lamivudine; ALT,
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HBeAg-negative
Patients were classified based on serum HBV DNA con-
centration and/or HBeAg status at cessation of lamivu-
dine therapy (Figure 1). In initially HBeAg-positive
patients, patients who showed serum HBV DNA <50
copies/mL with HBeAg loss were classified as Group A,
patients who showed serum HBV DNA 50-104 copies/
mL with HBeAg loss as Group B, and patients who
could not achieve HBeAg loss despite serum HBV DNA
50-104 copies/mL as Group C, and patients who showed
sustained serum HBV DNA ≥104 copies/mL irrespective
with achievement of HBeAg loss as Group D.
In initially HBeAg-negative patients, patients who
showed serum HBV DNA <50 copies/mL were classified
as Group A1, patients who showed HBV DNA 50-104 cop-
ies/mL as Group B1, and patients who showed sustained
HBV DNA ≥104 copies/mL as Group C1 (Figure 1).
Follow-up strategies for post-treatment outcomes
Patients were regularly followed up at a 1-2 month inter-
val for the first 6 months after cessation of lamivudine
and thereafter, they were followed up at a 3-6 month
interval [15]. Serum HBV DNA level, HBeAg/anti-HBe,
and serum ALT level were assayed at every visit after
cessation of lamivudine. Measurement of serum HBV
DNA level was performed by quantitative real-time PCR
using Abbott Real-time HBV quantification kits (detec-
tion limit: 50 copies/mL, Abbott Laboratories, USA). For
patients whose serum HBV DNA showed sustained ele-
vation above 104 copies/mL despite ALT normalization
with or without HBeAg seroconversion, lamivudine-
resistant mutations were genotyped using a restriction
fragment mass polymorphism method as previously
described [18].
Definition of antiviral response and post-treatment
outcomes
Virogic response was defined as decrease in serum HBV
DNA level below 104 copies/mL after lamivudine treat-
ment. Serologic response was defined as HBeAg loss/
seroconversion after lamivudine treatment in initially
HBeAg-positive patients.
Post-treatment outcomes after cessation of lamivudine
were categorized as virologic relapse, biochemical break-
through, hepatitis flare, and HBeAg reversion. Post-
treatment virologic relapse was defined as increase in
serum HBV DNA level above 104 copies/mL on 2 con-
secutive tests at least 1 month apart during follow-up
period after lamivudine cessation in patients who
showed virologic response at the time of lamivudine ces-
sation. Biochemical breakthrough was defined as in-
crease of ALT level above upper limit of normal (ULN,
40 IU/L) on 2 consecutive tests at least 1 month apartduring follow-up period after lamivudine cessation in
patients who had normalization of ALT at the time of
lamivudine cessation. Hepatitis flare was defined as ele-
vation of ALT level more than 10 times the ULN after
lamivudine cessation. HBeAg reversion was defined as
reappearance of HBeAg during follow-up period after
lamivudine cessation in patients who achieved HBeAg
loss in initially HBeAg-positive patients. These post-
treatment outcomes were analyzed according to classifi-
cation of patients with initially HBeAg-positive and
HBeAg-negative.
Statistical analyses
Differences between categorical or continuous variables
were analyzed using the chi-square test, Fisher’s exact
test, or Student t test. Cumulative post-treatment out-
comes were analyzed using Kaplan–Meier method and
log-rank test. Multivariate analyses of the potential pre-
dictors for virologic relapse and biochemical break-
through were performed using Cox’s proportional




The baseline characteristics of all the 138 patients at the
time of initiation and cessation of lamivudine therapy
are shown in Table 1. There were no significant differ-
ences in sex and serum level of ALT, albumin, and total
Bilirubin except age between initially HBeAg-positive
and HBeAg-negative patients. Median duration of lami-
vudine treatment was 35.5 months (range, 13-
98 months). Before initiation of antiviral treatment, liver
cirrhosis was observed in 17 of 138 patients, and none
of them had decompensated liver cirrhosis (Table 1).
In 102 initially HBeAg-positive patients, 83 (81.4%)
patients achieved serum HBV DNA <104 copies/mL at
cessation of lamivudine (Figure 1). Of these 83 patients,
42 (50.6%) patients showed serum HBV DNA <50 cop-
ies/mL with HBeAg loss (Group A), 37 (44.6%) showed
serum HBV DNA 50-104 copies/mL with HBeAg loss
(Group B), and 4 (4.8%) could not achieve HBeAg loss
despite serum HBV DNA 50-104 copies/mL (Group C).
Nineteen (18.6 ) out of 102 HBeAg-positive patients
showed sustained serum HBV DNA ≥104 copies/mL
with achievement of HBeAg loss (n = 2) and without it
(n = 17) (Group D) and the remaining 83(81.4%)
received the extended therapy for 12 months after
achievement of serum HBV DNA <50 (n = 42, 41.2%)
and 50-104 copies/mL (n = 41, 40.2%).
Thirty-seven patients of group B discontinued lamivu-
dine despite their HBV DNA level (50-104 copies/mL)
due to the economic burden for continuous medication,
the need for pregnancy (n = 3), or lamivudine-resistance
Table 1 Baseline characteristics of all 138 patients at the initiation and cessation of lamivudine treatment







Age (years) 39 (16-79) 37 (16-67) 45 (25-79) 0.001
Sex (male), n (%) 82 (59.4) 59 (57.8) 23 (63.9) 0.560
ALT (IU/L) 204 (41-1476) 214 (41-994) 164 (42-1476) 0.864
Albumin (g/dL) 3.9 (1.8-4.6) 3.9 (1.8-4.6) 4.0 (2.3-4.4) 0.664
Total bilirubin (mg/dL) 1.2 (0.4-22.1) 1.2 (0.4-22.0) 1.2 (0.5-22.1) 0.430
HBV DNA (Log10 copies/mL) 7.4 (5.0-10.0) 7.5 (5.0-10.0) 7.4 (5.4-9.1) 0.877
Liver cirrhosis 17 (12.3) 9 (8.8) 8 (22.2) 0.040
Characteristics at cessation of LAM n = 138 n = 102 n = 36 P-value
Age (years) 43 (19-82) 41 (19-69) 48 (28-82) 0.001
ALT (IU/L) 18 (5-38) 19 (7-38) 18 (5-38) 0.696
Albumin (g/dL) 4.1 (2.8-4.7) 4.1 (2.8-4.7) 4.1 (3.4-4.4) 0.518
Total bilirubin (mg/dL) 1.1 (0.5-1.8) 1.1 (0.6-1.8) 1.1 (0.5-1.2.0) 0.297
HBV DNA (copies/mL), n (%)† 0.006
<50 68 (49.3) 42 (41.2) 26 (72.2)
50-104 48 (34.8) 41 (40.2) 7 (19.4)
104 ≤ 22 (15.9) 19 (18.6) 3 (8.3)
HBeAg loss/seroconversion, n (%) NA 82 (80.4) NA
Treatment duration (month) 35.5 (13-98) 35.6 (13-98) 35.1 (14-80) 0.333
Data were presented as median (range).
ALT, alanine aminotransferase; LAM, lamivudine; NA, not applicable.
†Serum HBV DNA at cessation of lamivudine.
* P-value for difference between the Initial HBeAg-positive and HBeAg-negative groups.
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L180M; M204I without L180M (n = 1). Twenty-two
patients of group C and D discontinued lamivudine after
achievement of ALT normalization for more than 1 year
due to the economic burden for continuous medication
or lamivudine-resistance mutation: M204V (n = 11),
M204I (n = 1), and M204V/M204I (n = 1) with L180M;
M204V without L180M (n = 1).
In 36 initially HBeAg-negative patients, 26 (72.2%)
patients showed serum HBV DNA <50 copies/mL
(Group A1), 7 (19.4%) patients showed HBV DNA 50-
104 copies/mL (Group B1), and the remaining 3 (8.3%)
patients showed sustained HBV DNA ≥104 copies/mL
(Group C1) at cessation of lamivudine (Figure 1).
Thirty-three (91.7%) out of 36 HBeAg-negative patients
received extended therapy for 12 months after achieve-
ment of serum HBV DNA <50 (n = 26) and 50-104 cop-
ies/mL (n = 7).
Seven patients of group B1 discontinued lamivudine
after achievement of low viral loads although their
serum HBV DNA level was not less than 50 copies/mL
due to the economic burden for continuous medication
or lamivudine-resistance mutation (M204V with L180M,
n = 3). Three patients of group C1 discontinued lamivu-
dine after achievement of ALT normalization for morethan 1 year due to the economic burden for sustained
medication or lamivudine-resistance mutation (M204V
with L180M, n = 1).
Clinical course of initially HBeAg-positive patients after
lamivudine cessation
Among 102 initially HBeAg-positive patients, analysis of
virologic relapse was available in 83 patients who
achieved serum HBV DNA <104 copies/mL at cessation
of lamivudine, and biochemical breakthrough and hepa-
titis flare were analyzed in all 102 patients. During the
median follow-up period of 28 months after lamivudine
cessation, virologic relapse, biochemical breakthrough,
and hepatitis flare were observed in 44.6, 52.9, and
12.7% of patients, respectively. The 3-year cumulative
virologic relapse was significantly less common in
patients with serum HBV DNA <50 copies/mL than
patients with HBV DNA 50-104copies/mL (group A vs.
B: 34.4 vs. 60.9%, P = 0.037) (Figure 2A).
The 3-year cumulative biochemical breakthrough rates
in patients of group A, B, C, and D were 38.5, 62.6, 66.7,
and 90.9%, respectively. The patients with serum HBV
DNA >104 copies/mL showed significantly higher bio-
chemical breakthrough rate than the other patients
(group A vs. D, P <0.001; group B vs. D, P = 0.012)
Figure 2 Clinical courses of initial HBeAg-positive patients after lamivudine cessation. Virologic relapse (A), biochemical breakthrough (B),
hepatitis flare (C), and HBeAg reversion (D). Patients were grouped according to serum HBV DNA level and HBeAg status at cessation of
lamivudine treatment: Group A, HBV DNA <50 copies/mL with HBeAg loss; Group B, HBV DNA 50-104 copies/mL with HBeAg loss; Group C, HBV
DNA 50-104 copies/mL without HBeAg loss; Group D, HBV DNA ≥104 copies/mL irrespective HBeAg loss.
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was significantly higher in patients with serum HBV
DNA >104 copies/mL than the other patients (group A
vs. D: 4.8 vs.21.8%, P = 0.048; B vs. D: 11.9 vs.21.8%,
P = 0.042; C vs. D: 0% vs. 21.8%, P = 0.444; others, P > 0.05)
(Figure 2C). Hepatitis flare was not observed in patients
of group C although biochemical breakthrough was ob-
served in them.
Analysis of HBeAg reversion was available in 82
patients who achieved HBeAg loss at cessation of lami-
vudine. There was no significant difference in the 3-year
cumulative HBeAg reversion rate between group A and
B (21.3 vs.23.04%, P = 0.715), and 1 of 3 patient of group
D showed HBeAg reversion at 11 months after cessation
of lamivudine (Figure 2D).
Biochemical breakthrough was significantly higher in
patients who discontinued lamivudine after achievement
of HBeAg loss than who did not (P < 0.001) (Figure 3B).
However, virologic relapse and hepatitis flare did not
show significant association with serologic response at
cessation of lamivudine (P = 0.208 and P = 0.061, respect-
ively) (Figure 3A and 3C).Clinical course of initially HBeAg-negative patients after
lamivudine cessation
Among 36 initially HBeAg-negative patients, analysis of
virologic relapse was available in 33 patients with serum
HBV DNA <104 copies/mL at cessation of lamivudine.
Biochemical breakthrough and hepatitis flare were ana-
lyzed in all 36 patients.
During a median follow-up of 30 months after cessa-
tion of lamivudine, virologic relapse, biochemical break-
through, and hepatitis flare were observed in 27.3, 30.6,
and 11.8% of patients, respectively. The 3-year cumula-
tive virologic relapse was significantly less common in
patients with HBV DNA <50 copies/mL than those with
HBV DNA 50-104 copies/mL at the cessation of lamivu-
dine (group A1 vs. B1: 18.0 vs. 82.1%, P = 0.001)
(Figure 4A). The 3-year cumulative biochemical break-
through rate was significantly lower in patients with
HBV DNA <50 copies/mL than those with HBV DNA
50-104 copies/mL at cessation of lamivudine (group A1
vs. B1: 20.5 vs. 57.1%, P = 0.019) (Figure 4B). There
was no significant difference in the 3-year cumulative
hepatitis flare between groups A1 and B1 (6.3 vs. 33.3%,
Figure 3 Clinical courses after lamivudine cessation in initial HBeAg-positive patients according to serologic response. Virologic relapse
(A), biochemical breakthrough (B), and hepatitis flare (C).
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in group C.
Clinical course of retreated patients
Among 138 patients, 38 patients were retreated with
oral NAs due to virologic relapse or ALT elevation (≥2 x
ULN) (Table 2) and of these, 12 (31.6%) patients showed
hepatitis flare (≥10 x ULN). The median time interval
between lamivudine cessation and hepatitis flare was
8 months (range, 3-29 months). Eight (66.7%) of 12
patients with hepatitis flare showed virologic relapse at
the time of retreatment and 4 (33.3%) showed sustained
serum HBV DNA >104 copies/mL from the time of
lamivudine cessation. Fifteen (57.7%) of 26 patients with-
out hepatitis flare showed virologic relapse at the time of
retreatment and the remaining 11 (19.2%) patients
revealed sustained serum HBV DNA >104 copies/mL
from the time of lamivudine discontinuation.
Thirty (78.9%) of the retreated 38 patients received
entecavir. The other patients received lamivudine (n = 4),
clevudine (n = 3), and adefovir (n = 1) (Table 2).
Lamivudine-resistant mutation at the time of retreat-
ment in patients who were retreated with entecavir,
lamivudine, clevudine, and adefovir was detected in 4,2, 2, and 1 patients, respectively. In 2 of 4 patients who
were retreated with lamivudine, lamivudine resistant
mutation was detected after 10 days of antiviral retreat-
ment, and they were finally retreated with combination
therapy of lamivudine and adefovir based on the result
of lamivudine resistant mutation. During a median
follow-up of 18 months after antiviral retreatment, bio-
chemical and virologic responses were observed in 97.4
and 92.1% of retreated patients, respectively within me-
dian 1 year of retreatment. All of the 12 patients who
experienced hepatitis flare underwent retreatment and all
of them achieved ALT normalization and undetectable
serum HBV DNA level within median 5 and 9 months,
respectively. Only 1 patient required hospitalization at the
time of management for hepatitis flare without death.
After cessation of lamivudine therapy, virologic relapse
was observed in 48 (34.8%) out of 138 patients. Of these
48 patients, 23 (47.9%) patients were retreated as men-
tioned earlier and the remaining 25 patients have been
closely followed up without retreatment due to sustained
ALT normalization (n = 5) and mild serum ALT elevation
(<2 x ULN, n = 20). Among 22 patients who showed sus-
tained HBV DNA >104 copies/mL at the cessation of
lamivudine, 5 (25%) patients have been closely monitored
Figure 4 Clinical courses of initial HBeAg-negative patients after lamivudine cessation. Virologic relapse (A), biochemical breakthrough (B),
and hepatitis flare (C). Patients were grouped according to serum HBV DNA level at cessation of lamivudine treatment: Group A1, HBV DNA <50
copies/mL; Group B1, HBV DNA 50-104 copies/mL; Group C1, HBV DNA ≥104 copies/mL.
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(n = 4) and mild serum ALT elevation (<2 x ULN, n = 1).
Multivariate analysis for predictive factors of virologic
relapse and biochemical breakthrough after lamivudine
cessation
Of the 116 patients who achieved serum HBV DNA
<104 copies/mL at cessation of lamivudine, multivariate
analysis for virologic relapse showed that younger age
(<40 years) (Hazard ratio [HR] 0.520, P = 0.048) and
lower serum HBV DNA level (<50 copies/mL) (HR
0.507, P = 0.046) at cessation of lamivudine were in-
versely associated with post-treatment virologic relapse
in initially HBeAg-positive patients (Table 3). In initially
HBeAg-negative patients, lower serum HBV DNA level
(<50 copies/mL) at the cessation of lamivudine was in-
versely associated with post-treatment virologic relapse
(HR 0.186, P = 0.015). Younger age (<40 years) at cessa-
tion of lamivudine showed no statistical significance (HR
0.276, P = 0.236) (Table 3).
Out of a total of 138 patients, initial HBeAg-positive
(HR 2.435, P = 0.009), and higher serum HBV DNA level
at cessation of lamivudine (50-104 copies/mL, HR 1.847,
P = 0.043; ≥104 copies/mL, HR 5.249, P <0.001) wereindependently associated with post-treatment biochem-
ical breakthrough, but female (HR 0.372, P = 0.001) was
inversely associated with post-treatment biochemical
breakthrough (Table 4). However, there were no signifi-
cant risk factors for post-treatment hepatitis flare.
Discussion
We have shown here that the incidence of post-
treatment biochemical breakthrough as well as virologic
relapse was low in CHB patients who showed undetect-
able serum HBV DNA (<50 copies/mL) at cessation of
lamivudine after sufficient lamivudine treatment. Not-
ably, initially HBeAg-negative or female patients who
achieved low viral titer after sufficient lamivudine treat-
ment showed low post-treatment biochemical break-
through rate. In addition, we found that hepatitis flare
was infrequent and antiviral retreatment for CHB
patients with hepatitis flare was safe and effective al-
though virologic relapse and biochemical breakthrough
were common after cessation of lamivudine therapy.
The present study has distinctive features that we ana-
lyzed the comprehensive long-term post-treatment clin-
ical course including hepatitis flare and retreatment
results both in initially HBeAg-positive and HBeAg-
Table 2 Characteristics of the all 38 retreated patients with oral antiviral agents
Characteristics Total (n = 38) Initial HBeAg-positive (n = 31) Initial HBeAg- negative (n = 7)
At the time of retreatment
ALT (IU/L) 264 (81-895) 233 (83-895) 311 (81-575)
>2 x and ≤10 x ULN, n (%) 26 (68.4) 21 (67.7) 5 (71.4)
>10 x ULN, n (%) 12 (31.6) 10 (32.3) 2 (28.6)
HBV DNA (Log10copies/mL) 8.1 (5.3-9.7) 8.1 (5.3-9.7) 8.0 (5.8-8.9)
Time to hepatitis flare (months) * 8 (3-29) 7 (3-21) 18 (6-29)
Follow-up after cessation (months) 29 (2-43) 28 (2-43) 30 (3-42)
At the last follow-up after retreatment
ALT normalization, n (%) 37 (97.4) 31 (100) 6 (85.7)
Time to ALT normalization (months) 4 (1-21) 4 (1-21) 3 (3-26)
Serum HBV DNA level, n (%)
<50 copies/mL 24 (63.2) 19 (61.3) 5 (71.4)
50-104 copies/mL 11 (28.9) 9 (29.0) 2 (28.6)
≥104 copies/mL 3 (7.9) 3 (9.7) 0
Time to serum HBV DNA level (months)
<50 copies/mL 10 (3-33) 12 (1-33) 9 (3-26)
50-104 copies/mL 8 (1-31) 8 (1-31) 11 (3-26)
Hospitalization, n (%) 1 (2.6) 1 (3.2) 0 (0)
Retreatment drugs:
ETV/LAM/CLV/ADV, n (%) 30/4/3/1 27/2/2/0 3/2/1/1
(78.9/10.5/7.9/2.6) (87.1/6.5/6.5/0) (42.9/28.6/14.3/14.3)
Follow-up after retreatment (mo) 18 (2-39) 18 (2-39) 17 (6-33)
Data were presented as median (range).
ADV, adefovir; ALT, alanine aminotransferase; CLV, clevudine; ETV, entecavir; LAM, lamivudine; Mo, month; ULN, upper limit normal (40 IU/L).
* Time interval between lamivudine cessation and hepatitis flare.
Table 3 Multivariate analysis for virologic relapse after lamivudine cessation (n = 116)
HBeAg-positive patients
(n = 83)
Univariate analysis Multivariate analysis
HR 95% CI P-value HR 95% CI P-value*
Age at cessation (<40 years) 0.511 0.260-1.005 0.042 0.520 0.264-0.998 0.048
Sex (male) 1.038 0.538-2.003 0.910 - - -
Liver cirrhosis, presence 0.923 0.283-3.010 0.894 - - -
HBV DNA (Log10copies/mL)
+ 0.875 0.657-1.166 0.362 - - -
HBeAg loss at LAM cessation 2.503 0.599-10.459 0.209 - - -
Treatment duration (months) 0.990 0.974-1.007 0.258 - - -
HBV DNA levels (<50 copies/mL)† 0.489 0.257-0.971 0.041 0.507 0.261-0.987 0.046
HBeAg-negative patients (n = 33) HR 95% CI P-value HR 95% CI P-value
Age at cessation (<40 years) 0.188 0.023-1.510 0.116 0.276 0.033-2.314 0.236
Sex (male) 0.478 0.099-2.307 0.478 - - -
Liver cirrhosis, presence 1.689 0.433-6.591 0.451 - - -
HBV DNA (Log10copies/mL)
+ 0.509 0.276-1.151 0.354 - - -
Treatment duration (months) 0.994 0.950-1.040 0.781 - - -
HBV DNA levels (<50 copies/mL)‡ 0.145 0.038-0.552 0.005 0.186 0.048-0.723 0.015
C.I, confidence interval; HR, hazard ratio; LAM, lamivudine.
+Serum HBV DNA level at the initiation of lamivudine treatment.
‡Serum HBV DNA level at cessation of lamivudine treatment.
* Cox Proportional Hazards model with a backward elimination method.
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Table 4 Multivariate analysis for biochemical breakthrough after lamivudine cessation in all 138 patients
Variable Univariate analysis Multivariate analysis*
HR 95% C.I P-value HR 95% C.I P-value
Age at cessation (≥40 years) 1.001 0.611-1.639 0.998 - - -
Sex (female) 0.396 0.225-0.696 0.001 0.372 0.209-0.663 0.001
Initial HBeAg-positive 2.469 1.288-4.735 0.007 2.435 1.249-4.750 0.009
HBV DNA (Log10copies/mL)
+ 1.075 0.866-1.335 0.512 - - -
Total treatment duration (months) 1.000 0.987-1.013 0.957 - - -
HBV DNA levels (copies/mL) ‡
<50 (control)
50-104 2.515 1.402-4.514 0.002 1.847 1.018-3.350 0.043
≥104 5.656 2.964-10.793 <0.001 5.249 2.608-9.553 <0.001
C.I, confidence interval; HBV, hepatitis B virus; HR, hazard ratio.
+Serum HBV DNA level at initiation of lamivudine treatment.
‡Serum HBV DNA level at cessation of lamivudine treatment.
* Cox Proportional Hazards model with a backward elimination method.
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discussed in the previous studies [12,13,19,20], but bio-
chemical breakthrough, hepatitis flare, and retreatment
outcome were not closely investigated, especially in
HBeAg-negative patients. Post-treatment virologic re-
lapse and biochemical breakthrough incidence rates in
our study were low in patients who achieved undetect-
able serum HBV DNA level and were lower than those
of previous studies [12,13,21-24]. Moreover, patients in
our cohort were regularly and closely followed up after
cessation of lamivudine. Considering good results of NA
retreatment in relapsed patients, our data could be one
evidence for the importance of early detection and early
treatment of biochemical breakthrough before hepatitis
flare with close follow-up after cessation of lamivudine,
especially in patients with predisposing factors for post-
treatment biochemical breakthrough as well as virologic
relapse.
Despite that achievement of undetectable serum HBV
DNA level has been recommended as the endpoint of
CHB treatment [3,8,14,15], in fact, many clinicians have
used lamivudine continuously due to potential virologic
relapse, biochemical breakthrough, or hepatitis flare that
can occur after cessation of lamivudine. However, life-
long lamivudine treatment can induce drug resistance
mutation [6], and Asian patients tended to show less
durable serologic response than Western patients despite
long-term lamivudine use [22]. Considering these prac-
tical clinical settings, our results can provide useful evi-
dence for determining who can stop and when to stop
antiviral treatment. Furthermore, our data could
strengthen the previous recommendations that lamivu-
dine cessation might be reasonable option both in ini-
tially HBeAg-positive and HBeAg-negative patients who
achieved low viral titer after sufficient lamivudine
treatment.In terms of hepatitis flare after cessation of antiviral
agents, it has been one of the important concerns for
clinicians when they stopped antiviral agents in CHB
patients. It occurred in about 17-19% during the median
follow-up period of 3-6 months after lamivudine cessa-
tion in the previous studies [12,16,24-26], but they had
limits due to the small cohorts or short-term follow-up
period. In contrast, in our study, hepatitis flare was
observed only in 8.7% of all enrolled off-treated CHB
patients during the median follow-up period of
29 months. Thus, our results might be more acceptable
because our outcome was based on the long-term fol-
low-up period. In spite of our results, we have to say
that the cessation of antiviral agents should be very cau-
tious in patients with advanced liver disease because
hepatitis flare could cause devastating outcome in these
patients [16]. There should be sufficient discussion be-
tween doctor and patients about risk and benefit of con-
tinuation or cessation of antiviral agents, and frequent
follow-up scheme should be applied to these patients
with advanced liver disease if antiviral agent is cessated.
In multivariate analysis, serum HBV DNA level at the
cessation of lamivudine was independent predisposing
factor for post-treatment virologic relapse and bio-
chemical breakthrough. In addition, younger age at
lamivudine cessation was inversely associated with the
post-treatment virologic relapse, which was similar to
the previous studies [12,19], suggesting that younger
patients have more powerful immune responses than
older patients. Interestingly, we found that HBeAg-
negative or female patients who achieved low viral titer
were inversely associated with post-treatment biochem-
ical breakthrough. The relationship of female with lower
risk of post-treatment biochemical breakthrough was a
unique finding in our study that has not been discussed
in the previous literature. This result might be helpful
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we did not find the accurate mechanism for this rela-
tionship, hormonal difference might have influence on
this association. In addition, given the low incidence rate
of post-treatment biochemical breakthrough despite fre-
quent virologic relapse in HBeAg-negative patients of
our study, the association of HBeAg-negative patients
with low post-treatment biochemical breakthrough
might be explained by different virologic virulence or
immune response between initially HBeAg-positive and
HBeAg-negative patients. However, there need to be fur-
ther studies to elucidate the mechanism for these rela-
tionships in the future.
With regard to antiviral responsiveness in CHB
patients who received antiviral retreatment, it is an add-
itional important consideration when clinicians deter-
mine the cessation of antiviral therapy. To date, some
previous studies have reported about the clinical out-
come after retreatment, but the number of patients was
smaller without discussion of HBeAg-negative patients,
or the follow-up period after retreatment was shorter
compared to that of our study [12,19]. Interestingly, we
found that antiviral retreatment was safe and effective
even in patients with hepatitis flare. Moreover, most
re-treated patients achieved virologic and biochemical
response rapidly. Therefore, our results suggest that
lamivudine might be cautiously discontinued and inter-
mittent antiviral retreatment might be considered in
appropriately selected patients.
In terms of HBV genotype, which has been known to
be associated with the antiviral response to oral NA(s),
several previous researches performed in South Korea
have already demonstrated that approximately 100% of
the CHB patients in Korea had genotype C [27]. A vast
majority of patients in our cohort could be considered
to be infected by HBV genotype C. Thus, in the present
study, the relationship between HBV genotype and post-
treatment outcomes after lamivudine cessation could
not be analyzed.
This study had some limitations. First, our study is a
retrospective one that selection bias could be possible
For example, median serum HBV DNA level was not
different between patients with initial HBeAg positive
and HBeAg negative patients at the initiation of LAM
treatment as shown in Table 1, which was different from
the previous reports [28,29]. This finding might be
explained by the retrospective design or relatively small
number of initial HBeAg negative patients. However, we
tried to avoid selection bias by enrolling all the consecu-
tive patients including those who showed serum HBV
DNA level >104 copies/mL at cessation of lamivudine
in a given period. In addition, prospective trial for
off-treatment of NA is difficult to be performed because
of potential ethical problem. Second, we could notcompare antiviral efficacy among the patients who were
retreated by entecavir, lamivudine, clevudine, or adefovir
because of the small number of the patients. There need
to be further well-designed randomized prospective
studies with large sample size to compare the antiviral
efficacy among retreatment drugs.
Conclusions
Post-treatment virologic relapse and biochemical break-
through incidence rate were low in patients who
achieved low viral titer at lamivudine cessation. The inci-
dence of post-treatment biochemical breakthrough was
low in initially HBeAg-negative or female patients who
achieved low viral load after sufficient lamivudine treat-
ment. Moreover, antiviral retreatment in patients who
experienced virologic relapse or hepatitis flare after ces-
sation of lamivudine was safe and effective. Our findings
could be clinically useful evidence for cessation of lami-
vudine therapy despite the retrospective nature of this
study. In addition, intermittent antiviral therapy might
be cautiously considered in appropriately selected CHB
patients.
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